To assess whether this alternative splicing event occurs upon FBXO11 loss, we compared the frequency of EZH2 exon inclusion in SRSF2WT patient secondary AML samples stratified by FBXO11 expression (Fig. 4d, left panel). Here, EZH2 is linked to acute myeloid leukemia.